JOINTOWN PHARMACEUTICAL GROUP
JOINTOWN PHARMACEUTICAL GROUP, a leading player in the pharmaceutical industry, is headquartered in China and operates extensively across various regions. Founded in 1995, the company has established itself as a key provider of high-quality pharmaceutical products and services, focusing on areas such as drug distribution, manufacturing, and research and development. With a diverse portfolio that includes prescription medications, over-the-counter products, and healthcare services, JOINTOWN is recognised for its commitment to innovation and quality. The company has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. JOINTOWN PHARMACEUTICAL GROUP continues to set industry standards, making it a trusted name in healthcare solutions.
DitchCarbon Score
How does JOINTOWN PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
JOINTOWN PHARMACEUTICAL GROUP's score of 24 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
JOINTOWN PHARMACEUTICAL GROUP's reported carbon emissions
In 2024, JOINTOWN PHARMACEUTICAL GROUP reported total carbon emissions of approximately 47,929,410 kg CO2e, comprising 36,924,210 kg CO2e from Scope 1 emissions and 11,005,200 kg CO2e from Scope 2 emissions. This data highlights the company's ongoing commitment to monitoring and managing its carbon footprint. In the previous year, 2023, the company recorded Scope 1 emissions of about 318,939,120 kg CO2e, with significant contributions from mobile combustion (2,405,420 kg CO2e) and stationary combustion (4,334,300 kg CO2e). However, there is no reported data for Scope 2 or Scope 3 emissions for that year. Despite the substantial emissions figures, JOINTOWN PHARMACEUTICAL GROUP has not disclosed specific reduction targets or initiatives aimed at decreasing its carbon emissions. The absence of defined climate pledges or science-based targets suggests that the company may still be in the early stages of formalising its climate commitments. Overall, while JOINTOWN PHARMACEUTICAL GROUP has made strides in emissions reporting, further transparency regarding reduction strategies and long-term climate goals would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 318,939,120 | 00,000,000 |
| Scope 2 | - | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
JOINTOWN PHARMACEUTICAL GROUP is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
